Cat. No.: HY-B1899A

Taurodeoxycholic acid sodium hydrate

(Synonyms: Taurodeoxycholate sodium hydrate)

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway.

For research use only. We do not sell to patients.

Purity: 99.75%
CAS No.: 110026-03-4
Formula: C₂₆H₄₆NNaO₇S
Molecular Weight:539.70

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Taurodeoxycholic acid sodium hydrate Chemical Structure

CAS No.: 110026-03-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

Microbial Metabolite

All Endogenous Metabolite Isoforms :

In Vitro

The median plasma concentration of Taurodeoxycholate is 33.9 nM in healthy individuals^[1].
Taurodeoxycholate inhibits the binding of N-³H-methylscopolamine to the M3 muscarinic receptor of acetylcholine with an IC₅₀ of 170 μM^[1].
Taurodeoxycholate (0.05-1.00 mM; 1-6 days) stimulates intestinal epithelial cell proliferation^[2].
Taurodeoxycholate (0.05-1.00 mM; 24 h) induces a significant increase in S-phase concentration and a significant decrease in G1-phase concentration of the cell cycle, increases c-myc protein and mRNA expression in IEC-6 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

IEC-6 and caco-2 cells
Concentration:

0, 0.05, 0.50, and 1.00 mM
Incubation Time:

1, 2, 4 and 6 days
Result:

Significantly stimulated intestinal epithelial cell proliferation in a dose-dependent manner.

Cell Cycle Analysis^[2]

Cell Line:

IEC-6 cells
Concentration:

0, 0.05, 0.50, and 1.00 mM
Incubation Time:

24 h
Result:

Significantly increased cells in S phase and decreased cells in G1-phase.

Western Blot Analysis^[2]

Cell Line:

IEC-6 cells
Concentration:

0.5 mM
Incubation Time:

1 and 6 days
Result:

Significantly increased c-myc protein expression.

In Vivo

Taurodeoxycholate (0.5 mg/kg; i.v.; once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis^[1]
Dosage:

0.5 mg/kg
Administration:

Intravenous injection, 30 min or 24 h after LPS injection
Result:

Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice.

Chemical Information

CAS No. 110026-03-4
Appearance Solid
Molecular Weight 539.70
Formula C₂₆H₄₆NNaO₇S
Color White to off-white
SMILES

C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C.O
Synonyms

Taurodeoxycholate sodium hydrate
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (4)

All RT-PCR

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Adv Sci (Weinh)

Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. [Abstract]

2025 Mar;12(12):e2411719. PMID: 39899681

Taurodeoxycholic acid sodium hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]

The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.
Biomedicines

The Elevation and Impact of Peripheral Bile Acids in Chronic Lymphocytic Leukemia. [Abstract]

2025 Apr 4;13(4):874. PMID: 40299495
Metabolomics

2026 Jun 18;22(4):103.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (185.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8529 mL

9.2644 mL

18.5288 mL

5 mM

0.3706 mL

1.8529 mL

3.7058 mL

10 mM

0.1853 mL

0.9264 mL

1.8529 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 20 mg/mL (37.06 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chang S, et al. Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice. Front Immunol. 2018 Sep 18;9:1984. [Content Brief]

[2]. Yamaguchi J, et al. Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression. Surgery. 2004 Feb;135(2):215-21. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8529 mL	9.2644 mL	18.5288 mL	46.3220 mL
	5 mM	0.3706 mL	1.8529 mL	3.7058 mL	9.2644 mL
	10 mM	0.1853 mL	0.9264 mL	1.8529 mL	4.6322 mL
	15 mM	0.1235 mL	0.6176 mL	1.2353 mL	3.0881 mL
	20 mM	0.0926 mL	0.4632 mL	0.9264 mL	2.3161 mL
	25 mM	0.0741 mL	0.3706 mL	0.7412 mL	1.8529 mL
	30 mM	0.0618 mL	0.3088 mL	0.6176 mL	1.5441 mL
	40 mM	0.0463 mL	0.2316 mL	0.4632 mL	1.1581 mL
	50 mM	0.0371 mL	0.1853 mL	0.3706 mL	0.9264 mL
	60 mM	0.0309 mL	0.1544 mL	0.3088 mL	0.7720 mL
	80 mM	0.0232 mL	0.1158 mL	0.2316 mL	0.5790 mL
	100 mM	0.0185 mL	0.0926 mL	0.1853 mL	0.4632 mL

Keywords

Taurodeoxycholic acid sodium hydrate

4 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Taurodeoxycholic acid sodium hydrate

Bioactive Compound Library Max

Bioactive Compound Library

GPCR/G Protein Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Food-Sourced Compound Library

Targeted Diversity Library

Human Metabolite Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Bile Acids Library

Mass Spectrometry Human Metabolite Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Taurodeoxycholic acid sodium hydrate

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Taurodeoxycholic acid sodium hydrate Related Classifications

HY-B1899A Related Classifications